Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000495314 | SCV000578831 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-06-29 | reviewed by expert panel | curation | Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/). |
Ambry Genetics | RCV000218754 | SCV000274312 | likely benign | Hereditary cancer-predisposing syndrome | 2015-03-04 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000541649 | SCV000635738 | likely benign | Hereditary breast ovarian cancer syndrome | 2024-11-13 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000218754 | SCV000903696 | likely benign | Hereditary cancer-predisposing syndrome | 2018-02-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781091 | SCV000918908 | likely benign | not specified | 2019-08-21 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000218754 | SCV002532022 | likely benign | Hereditary cancer-predisposing syndrome | 2020-11-06 | criteria provided, single submitter | curation | |
Ce |
RCV003389764 | SCV004132999 | likely benign | not provided | 2022-03-01 | criteria provided, single submitter | clinical testing | BRCA2: BP4, BP7 |
BRCAlab, |
RCV000495314 | SCV004243867 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |